Tilray Brands, Inc.
HealthcareNASDAQ:TLRY · NASDAQ Global Select
-$0.14 today
Vol 3.14M · Avg 4.67M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-144.7%
avg -51.8%
ROIC
-115.9%
avg -21.0%
ROA
-103.3%
avg -15.8%
Analysis
ROA is currently the strongest return metric at -103.3% versus its period average of -15.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Irwin David Simon | President, Chief Executive Officer & Chairman | $5.57M | — | 68 | $0.00 | <0.01% |
Denise Menikheim Faltischek | Chief Strategy Officer and Head of M&A | $1.31M | — | 53 | $874,564.00 | 0.73% |
Mitchell S. Gendel | Global General Counsel & Corporate Secretary | $1.20M | — | 60 | $0.00 | <0.01% |
Carl A. Merton | Chief Financial Officer & Principal Accounting Officer | $959,237.00 | — | 56 | $920,497.00 | 0.77% |
Roger Savell | Chief Administrative Officer & Chief Financial Officer of International | $871,176.00 | — | 64 | — | — |
Berrin Noorata | Chief Corporate Affairs Officer | — | — | — | — | — |
Lloyd Brathwaite | Chief Information Officer | — | — | — | — | — |
Rajnish Ohri | President of International | — | — | 64 | — | — |
Nyree Pinto | Chief Human Resources Officer | — | — | — | — | — |
Blair MacNeil | President of Tilray Canada | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$123,540.90
Sells
1
$232,878.64
Net Sentiment
$109,337.74
Net selling
Most Active
Hopkinson David G.
1 transactions
Analysis
Insiders reported 3 buys worth $123,540.90 and 1 sells worth $232,878.64 over the last 12 months. That adds up to net selling of $109,337.74. Hopkinson David G. was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +21.8% (14yr)4 analysts |
| Revenue | N/A | N/A | N/A | +48.9% (14yr)6 analysts |
| Net Income | N/A | N/A | N/A | +50.8% (14yr)6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Net Income at +50.8% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Neogen Corporation
NASDAQ:NEOG
$1.98B
Dynavax Technologies Corporation
DVAX
$1.82B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Alvotech
NASDAQ:ALVO
$1.30B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B
Evotec SE
NASDAQ:EVO
$966.11M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
Who manages TLRY?
Tilray Brands, Inc. (TLRY) lists 10 active executives. The top listed executive is Carl A. Merton, Chief Financial Officer & Principal Accounting Officer.
Are TLRY insiders buying or selling?
Recent insider activity shows net buying of $8.54M.
Explore More
Continue the stock analysis
Jump to another research area for this company.